GZBL(SZ:002424) Shang Hai Zheng Quan Bao·2025-08-19 19:52Core Viewpoint - The company aims to strengthen its leading position in the苗药 (Miao medicine) sector and strives to become a competitive player in the中成药 (traditional Chinese medicine) industry through comprehensive competitiveness enhancement and strategic initiatives [6]. Company Overview - The company reported a revenue of 1.462 billion yuan and a net profit attributable to shareholders of 51.83 million yuan during the reporting period [6]. - The company has completed its internal control rectification, marking a return to normal operations, with its stock name changing from "ST百灵" to "贵州百灵" [6]. Financial Information - The company does not plan to distribute cash dividends or issue bonus shares during the reporting period [3]. - The board of directors approved the half-year report and its summary, which reflects the company's actual situation accurately and completely [12][23]. Strategic Goals - The company focuses on "technology苗药, culture苗药, ecological苗药" as key strategies to enhance its manufacturing, marketing, innovation, and integration platforms [6]. - Continuous investment in technology and improvement in management and marketing capabilities are emphasized to enhance production quality and cost control [6].